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We aimed to determine associations between multiple vascular risk factors (VRF) at w73 years and
progression of white matter hyperintensities (WMH) from w73 years to w76 years. We calculated
correlations and generalized estimating equation models of a comprehensive range of VRF at 73 years
and change in WMH volume from 73 years to 76 years. Higher systolic (rho ¼ 0.126, p ¼ 0.009) and
diastolic (rho ¼ 0.120, p ¼ 0.013) blood pressure at 73 years were signiﬁcant predictors for greater WMH
volume at 76 years in a simple correlation model. However, neither measured blood pressure nor self-
reported hypertension at 73 years was signiﬁcant predictors of WMH volume change in a fully
adjusted model which accounted for initial WMH volume at 73 years. Lower high-density lipoprotein
cholesterol (beta ¼ 0.15 % intracranial, 1.80 mL; p < 0.05) and current smoking (beta ¼ 0.43 %
intracranial, 5.49 mL; p < 0.05) were the only signiﬁcant VRF predictors of WMH volume change from
73 years to 76 years. A focus on smoking cessation and lipid lowering, not just antihypertensives, may
lead to a reduction in WMH growth in the eighth decade of life.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Brain white matter hyperintensities (WMH) are common in
community-dwelling older people and are associated with cogni-
tive decline, dementia, stroke, and death (Brickman et al., 2012;
Debette and Markus, 2010; Ritchie et al., 2015; Silbert et al., 2012;
Valdés Hernández et al., 2013). It is therefore important to clarify
the role of potentially modiﬁable targets, such as vascular risk
factors (VRF; de Leeuw et al., 2002; Dufouil et al., 2001; Marcus
et al., 2011; Murray et al., 2005), for intervention in progression of
WMH.tely, Drs. Deary and Wardlaw
s, Centre for Clinical Brain
4TJ, UK. Tel.: þ44 (0)131 465
rdlaw).
Inc. This is an open access articleSeveral cohort studies have assessed longitudinal WMH pro-
gression over approximately 2e6 years (Debette et al., 2011;
Dufouil et al., 2001; Gottesman et al., 2010; Guo et al., 2009;
Longstreth et al., 2005; Marcus et al., 2011; Sachdev et al., 2007;
Schmidt et al., 1999, 2003, 2012; Taylor et al., 2003; van Dijk
et al., 2008; Veldink et al., 1998; Wahlund et al., 1996). The stron-
gest predictor of WMH progression appeared to be baseline WMH,
where participants with the greatest volume of WMH at baseline
had the greatest increases in WMH volume (Sachdev et al., 2007;
Schmidt et al., 1999, 2003, 2007; Taylor et al., 2003; Veldink et al.,
1998). These longitudinal studies mostly included participants
across a wide age range and/or in midlife, assessed individual or
few VRF (rather than combined VRF), used qualitative visual ratings
for WMH progression, or did not measure baseline WMH (e.g., de
Leeuw et al., 2002; Dufouil et al., 2001; Marcus et al., 2011).
The results of these previous studies conﬂict on the signiﬁcance
of VRF in progression of WMH. Some reported that hypertensionunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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WMH volumes over time (e.g., de Leeuw et al., 2002; Debette et al.,
2011; Dufouil et al., 2001; Gottesman et al., 2010; Guo et al., 2009;
Longstreth et al., 2005; Marcus et al., 2011; Schmidt et al., 1999; van
Dijk et al., 2008; Veldink et al., 1998), whereas others found that
blood pressurewas not associatedwithWMHprogression (Sachdev
et al., 2007; Schmidt et al., 2003; Taylor et al., 2003). The signiﬁ-
cance of smoking and cholesterol is also unclear from these prior
studies (Debette et al., 2011; Sachdev et al., 2007; van Dijk et al.,
2008), and one study found that no VRF were associated with
WMH progression (Sachdev et al., 2007).
One reason for the conﬂict between previous reports may be
their varying age ranges, and this suggests that different VRF may
have differential effects on WMH throughout life. For example, the
effect of blood pressure is strong in midlife (Debette et al., 2011) but
apparently reduces after 70 years (van Dijk et al., 2008); whereas
greater cross-sectional associations between cholesterol and WMH
have been identiﬁed after 70 years (Ryu et al., 2014). Given that
these potentially differential effects were identiﬁed in wide age
ranges and cross-sectionally, it is important to clarify the signiﬁ-
cance of individual and combined VRF (Bangen et al., 2015; Maillard
et al., 2015) in longitudinal WMH progression at speciﬁc ages. This
is particularly true in the eighth decade of life where the risk of
dementia increases substantially (Matthews et al., 2005).
Although birth cohorts may be limited in their generalizability
by the range of environmental exposures represented, this study
design allows the possibility to test the inﬂuence of individual and
combined VRF associations in a large age-homogenous sample that
mitigates against the strong effect of even small differences in age
on WMH (Aribisala et al., 2014). None of the numerous previous
studies that we have identiﬁed tested associations between WMH
and a comprehensive range of VRF exclusively in the eighth decade
of life.
With a homogenous sample of 439 community-dwelling par-
ticipants from the Lothian Birth Cohort 1936 (LBC1936; Deary et al.,
2007, 2012; Wardlaw et al., 2011), we aimed to determine the
contribution of multiple VRF at w73 years to progression in WMH
volume fromw73 years tow76 years.
2. Material and methods
We followed “Strengthening the Reporting of Observational
Studies in Epidemiology statement: guidelines for reporting
observational studies” in preparation of this article (von Elm et al.,
2007).
2.1. Standard protocol approvals, registrations, and patient consents
Approval for the LBC1936 study protocol was obtained from the
Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/
56) and Lothian Research Ethics Committee (LREC/2003/2/29). All
participants gave written, informed consent.
2.2. Participants
A total of 1091 (548, 50% male) community-dwelling partici-
pants in the Lothian area were recruited into the LBC1936 cohort
study between 2004 and 2007 (Deary et al., 2007, 2012). Most
participants completed the ScottishMental Survey of 1947, inwhich
almost all Scottish school children born in 1936 and attending
school in June 1947 were cognitively tested. Of the 1091 partici-
pants initially recruited, 681 (362, 53% male) participants
completed baseline brain magnetic resonance imaging (MRI) at
mean age 72.7 years (standard deviation 0.7, range 71.1e74.3 years).
Of the 681 participants with baseline brain MRI, 439 participants(n ¼ 250, 55% male) returned for follow-up brain MRI at mean age
76.4 years (standard deviation 0.64, range 74.9e77.8 years) and had
Mini Mental State Examination (MMSE) scores 24 at baseline and
follow-up. We excluded subjects with possible dementia
(MMSE<24) at either time point (n ¼1 2). It is the 439 participants
with full brain imaging data and normal range MMSE at 73 and
76 years, which were used in the present analysis.
2.3. VRF assessment
According to previously published methods (Deary et al., 2007,
2012; Wardlaw et al., 2014), we measured several VRF during a
Clinical Research Facility assessment at 73 years: systolic and dia-
stolic blood pressure, total cholesterol, high-density lipoprotein
(HDL) cholesterol ratio to total cholesterol (henceforth referred to
as, “HDL cholesterol ratio”), and glycated hemoglobin (HbA1c). We
used the average of 3 standing and 3 sitting systolic and diastolic
blood pressure readings from an Omron 705IT monitor. We also
included the after VRF by self-report: diagnosis of hypertension,
hyperlipidemia, diabetes, history of cardiovascular disease, and
smoking category (never, ex, and current).
2.4. Brain MRI acquisition and processing
Full brain MRI acquisition parameters were described previously
(Wardlaw et al., 2011). Brieﬂy, all participants had brain MRI on the
same 1.5 T GE Signa Horizon HDx clinical scanner (General Electric,
Milwaukee, WI, USA) maintained on a careful quality assurance
program. The scanner and scanning protocol were the same at 73
and 76 years and acquired T1-, T2-, T2*-, and ﬂuid attenuated
inversion recovery-weighted images (Wardlaw et al., 2011).
We measured intracranial (ICV), whole brain, and WMH vol-
umes in mL using a validated multispectral image processing
method that combines T1-, T2-, T2*-, and ﬂuid attenuated inversion
recovery-weighted MRI sequences for segmentation (Valdés
Hernández et al., 2010). All sequences were coregistered and tis-
sue volumes estimated by cluster analysis of voxel intensities. Ac-
cording to STandards for ReportIng Vascular changes on
nEuroimaging, we explicitly deﬁned WMH as punctate, focal, or
diffuse lesions in all subcortical regions (Wardlaw et al., 2013).
WMH masks were manually edited by following STandards for
ReportIng Vascular changes on nEuroimaging guidelines and using
3D-mask editing software, Multi-Image Analysis GUI (MANGO;
http://ric.uthscsa.edu/mango/). Editing was overseen by a consul-
tant neuroradiologist (JoannaM.Wardlaw). Cortical and subcortical
infarcts were manually removed from WMH volumes during the
editing process. We manually checked all segmented images for
accuracy blinded to all clinical details, corrected errors, and
excluded imaging-detected infarcts from WMH volumes (Wang
et al., 2012).
2.5. Statistical analyses
2.5.1. WMH volume distributions, changes and associations with
VRF
Statistical analyses were performed in the Statistical Analysis
System (SAS) version 9.4 (2002e2012 SAS Institute Inc.) and Matrix
Laboratory (MATLAB) R2014a (1994e2014 The MathWorks, Inc.).
Log transforming the positively skewed WMH distributions had
little effect on our results, and therefore, we maintained their
original scale (proportion of ICV) to simplify interpretation. We
assessed changes in WMH and whole brain volumes from 73 years
to 76 years using paired t-tests. We calculated Pearson correlations
between volumes and Spearman correlations between VRF because
a number of the VRF were categorical.
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associations between VRF at 73 years and change in WMH from
73 years to 76 years
We used GEE, “PROC GENMOD” in SAS (SAS Institute Inc., 2010),
to model associations between VRF at 73 years and change inWMH
volume from 73 years to 76 years (Schmidt et al., 2003; Twisk,
2003). We controlled for overall head size in the ﬁrst GEE model
by dividing WMH volume by ICV and in a second model with raw
WMH volume as the dependent variable and ICV included as an
independent variable. We modeled smoking as a “dosage,” i.e.,
linear, variable (Karama et al., 2015), and as a categorical variable in
2 separate GEE. We adjusted GEE models for cardiovascular disease
history, gender, and body mass index as in previous studies
(Debette et al., 2011; Schmidt et al., 1999). We tested the variance
inﬂation factor (VIF) of each independent variable using “PROC
REG” in SAS to identify potential multicollinearity and volatile
regression estimates. VIF 10 may indicate problematic multi-
collinearity (Belsley et al., 1980). Although systolic and diastolic
blood pressures are highly correlated, we maintained both as
separate independent variables (rather than pulse pressure)
because their respective VIF were approximately 1.5 each. The VIF
of low-density lipoprotein cholesterol was 13.2, and therefore, we
only included HDL cholesterol ratio and total cholesterol in our GEE
models. All other variables had VIF below 5.
3. Results
3.1. Changes in WMH and whole brain volume from 73 years to
76 years
Mean changes in WMH and whole brain volume from 73 years
to 76 years are summarized in Table 1 and Fig. 1. Whole brain vol-
ume generally decreased with age (paired Cohen’s d of
change ¼ 0.95), and WMH volume generally increased with age
(paired Cohen’s d of change ¼ 0.95).
The mean WMH volume of 11.9  11.7 mL at 73 years and
15.914.6 mL at 76 years (Table 1) indicates a relative mean in-
crease of 33.6% over 3 years (4.0 mL  4.3 mL or 0.28%  0.29% of
ICV). This growth of WMH was generally in the lateral superior
direction, extending centrifugally from the ventricles and superi-
orly toward the vertex, with less growth posteriorly in the occipital
poles (Fig. 2).
Fig. 1 shows that there was increased growth of WMH volume
from 73 years to 76 years in those with biggerWMH volumes at age
73 years. There was a strong correlation between WMH volume at
73 years and 76 years (r ¼ 0.97, p < 0.0001). Bigger raw WMH
volumes at 76 years were associated with bigger raw whole brain
volumes at 73 years (r¼ 0.14, p ¼ 0.003), but ICV normalized whole
brain volume at 73 years was not associated with ICV normalized
WMH volume at 76 years (r ¼ 0.002, p ¼ 0.97).
Participants who did not return at 76 years had slightly smaller
whole brain volumes at 73 years compared with participants who
did return (68.5 %ICV vs. 69.1 %ICV; t ¼ 2.98, p ¼ 0.0030). How-
ever, participants who did not return at 76 years did not have bigger
WMH volumes at 73 years (0.92 %ICV vs. 0.83 %ICV; t ¼ 1.21,
p ¼ 0.2258).Table 1
Mean  SD volumes of whole brain and WMH at 73 y and 76 y
Structure Mean  SD volume at 73 y, %ICV (mL) Mean  SD volume at 76 y, %IC
Whole brain 69.05  2.12 (994.6  92.4) 67.82  2.17 (975.8  90.8)
WMH 0.83  0.81 (11.9  11.7) 1.10  1.00 (15.9  14.6)
Key: ICV, intracranial; SD, standard deviation; WMH, white matter hyperintensities.
a Cohen’s d were calculated using mean and SD volume change %ICV, i.e., changes in %3.2. Prevalence of VRF
The prevalence of VRF at 73 years did not signiﬁcantly differ
between participants who returned and those who did not return
for follow-up (Table 2). The longitudinal changes in prevalence of
VRF in returning subjects are in Table 3.
Therewere signiﬁcant increases in the incidence of self-reported
hypertension, hyperlipidemia, and history of cardiovascular dis-
ease; there was a signiﬁcant average increase in HbA1c and
decrease in total cholesterol from 73 years to 76 years (Table 3).
3.3. Spearman correlations between VRF at 73 years and WMH
volume at 73 years and 76 years
There was a negative correlation between HDL cholesterol ratio
at 73 years and WMH volume at 76 years (rho ¼ 0.178, p < 0.001)
and positive correlations with systolic (rho ¼ 0.126, p ¼ 0.009) and
diastolic (rho ¼ 0.120, p ¼ 0.013) blood pressure at 73 years and
WMH volume at 76 years. Associations between VRF at 73 years
and WMH at 73 years were approximately equal to associations
between VRF at 73 years andWMH at 76 years (Table 4). Smoking at
73 years was not a signiﬁcant predictor of WMH at 76 years in this
simple correlation model.
3.4. GEEs of associations between VRF at 73 years and WMH change
from 73 years to 76 years
GEE of associations between VRF at 73 years and change in
WMH volume from 73 years to 76 years are summarized in Table 5.
Lower HDL cholesterol and current smoking (entered as binary
variable) were the only signiﬁcant VRF predictors of increased
WMH growth from 73 years to 76 years (Table 5). Smoking was not
a signiﬁcant predictor when considering it as a “dosage,” i.e., linear
variable, in either the “%ICV” or “mL” models (beta ¼ 0.1272 %ICV,
1.7120 mL; standard error ¼ 0.0736 %ICV, 0.9875 mL; Z ¼ 1.73, 1.73;
p ¼ 0.0840, 0.0830). Gender was a signiﬁcant predictor of growth
when raw WMH volumes were the dependent variables, and ICV
was entered as a model predictor; with females having greater
WMH growth than males (Table 5).
4. Discussion
We have found, from a comprehensive range of VRF, that lower
HDL cholesterol ratio and current smoking at 73 years were asso-
ciated with increased WMH volume progression from 73 years to
76 years. Higher diastolic and systolic blood pressure at 73 years
appeared to be signiﬁcant predictors of greater WMH volume at
76 years in a simple correlation model. However, neither measured
blood pressure nor self-reported hypertension at 73 years were
signiﬁcant predictors of WMH volume change in a GEE model
which accounted for initial WMH volume at 73 years. Females
appeared to have increased rates of change in WMH when
modeling rawWMH volumes as dependent variables and including
ICV as an independent variable.
Previous studies of VRF and WMH have found that, rather than
cholesterol and smoking, higher blood pressure is the greatestV (mL) Mean  SD volume change, %ICV (mL) Cohen’s d of changea p value
1.23  1.29% (18.8  19.5) 0.95 <0.0001
0.28  0.29 (4.0  4.3) 0.95 <0.0001
ICV were d SD different to zero.
Fig. 1. Plots of WMH and whole brain volume at 73 years and 76 years. Scatter plots of WMH volume at 73 years andWMH volume at 76 years (raw left top panel, ICV corrected right
top panel); difference versus mean plots of WMH volume at 73 years and WMH volume at 76 years (raw left middle panel, ICV corrected right middle panel); and whole brain
volume at 73 years and WMH volume at 76 years (raw left bottom panel, ICV corrected right bottom panel). Abbreviations: ICV, intracranial volume; WMH, white matter
hyperintensities.
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et al., 2002; Debette et al., 2011; Gottesman et al., 2010; Guo
et al., 2009; Longstreth et al., 2005; Marcus et al., 2011; Schmidt
et al., 1999; van Dijk et al., 2008; Veldink et al., 1998), and there
are a number of possible reasons for this discord. These studies
generally had younger participants than studied here and/or had a
wide age range of participants, included one or few VRF, did not
account for baseline WMH volume, and/or used qualitative WMH
ratings. Our results are consistent with the Rotterdam Scan Study
of a wider age range that found the associations between blood
pressure and WMH to signiﬁcantly reduce after 70 years (van Dijk
et al., 2008); the Austrian Stroke Prevention Study which found an
association with hypertension to disappear when consideringbaseline WMH (Schmidt et al., 2003); a recent cross-sectional
study that found higher cholesterol was associated with bigger
WMH in subjects aged 70 years but not in younger subjects (Ryu
et al., 2014); and with recent neutral results between blood
pressure lowering and WMH volume in randomized clinical trials
(Weber et al., 2012). Considering existing literature and the results
from our study, there is increasing support for the theory that VRF
have differing effects on WMH progression at different stages of
life. Our results suggest that nonsmoking and higher HDL
cholesterol levels are associated with less growth of WMH in the
eighth decade of life, giving support to further age-speciﬁc trials of
lipid lowering and lifestyle modiﬁcation to prevent progressive
vascular brain damage.
Fig. 2. Growth of WMH volume from 73 years to 76 years. The blue volume shows where 95% of WMH occurred at 73 years. The red volume shows where 95% of the growth in
WMH occurred from 73 years to 76 years. The beige volume is mean brain volume at 73 years. Abbreviation: WMH, white matter hyperintensities.
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considered as a “dosage” (i.e., linear) variable in the GEE model
compared with when considering it as a categorical variable. There
is methodologic support for both approaches. The categorical
approach may be favored because linear variables generally consist
of continuous data (categories are not continuous). The dosage
approach may be considered favorable in these data where only a
small percentage (w6%) of subjects were current smokers at
73 years, and results are based on unbalanced participant groups.
However, in previous work with a more balanced sample of currentTable 2
Prevalence of VRF between returning and nonreturning subjects
Measure Returners Nonreturners Test statistic, p-value
Systolic blood
pressure at 73 y
146  18 mmHg 146  15 mmHg t ¼ 0.03, p ¼ 0.975
Diastolic blood
pressure at 73 y
79  9 mmHg 80  8 mmHg t ¼ 0.35, p ¼ 0.724
HDL cholesterol
ratio at 73 y
3.7  1.1 3.8  1.1 t ¼ 0.52, p ¼ 0.600
HbA1c at 73 y 5.7  0.6 DCCT 5.7  0.5 DCCT t ¼ 0.75, p ¼ 0.451
Cardiovascular
disease at 73 y
26.2% 28.7% z ¼ 0.55, p ¼ 0.292
Hypertension at
73 y
48.2% 53.3% z ¼ 1.00, p ¼ 0.158
Hyperlipidemia at
73 y
42.2% 37.7% z ¼ 0.90, p ¼ 0.184
Total cholesterol at
73 y
5.2  1.2 mmol/L 5.1  1.0 mmol/L t ¼ 0.25, p ¼ 0.805
Diabetes at 73 y 9.0% 9.8% z ¼ 0.30, p ¼ 0.382
Smoking at 73 y 6.2% 8.2% z ¼ 0.80, p ¼ 0.212
BMI at 73 y 27.8  4.3 28.1  4.7 t ¼ 0.68, p ¼ 0.495
Key: BMI, body mass index; DCCT, Diabetes Control and Complications Trial; HbA1c,
glycated hemoglobin; HDL, high-density lipoprotein; VRF, vascular risk factors.and nonsmokers, current smokingwas the strongest VRF associated
with brain vascular damage when considered as a total burden of
small vessel disease (Staals et al., 2014). This suggests that the
categorical approach may be the most suitable one for assessing
associations between smoking and vascular brain damage, but
future work is required to conﬁrm this.
Gender was not a signiﬁcant predictor of WMH change when
considering WMH as a proportion of ICV; however, females had
signiﬁcantly higher rates of change when raw WMH volumes were
corrected by inclusion of ICV as an independent variable. Previous
work in a multiple sclerosisematched control study (n ¼ 36) foundTable 3
Longitudinal changes in VRF in returning subjects
Measure Baseline (73 y) Follow-up (76 y) Test statistic, p-value
Systolic blood
pressure
146  18 mmHg 147  19 mmHg t ¼ 0.71, p ¼ 0.480
Diastolic blood
pressure
79  9 mmHg 80  10 mmHg t ¼ 1.81, p ¼ 0.072
HDL cholesterol
ratio
3.7  1.1 3.7  1.0 t ¼ 1.23, p ¼ 0.220
HbA1c 5.7  0.6 DCCT 5.9  0.7 DCCT t ¼ 4.57, p < 0.001*
Cardiovascular
disease
26.2% 32.4% z ¼ 2.08, p ¼ 0.019*
Hypertension 48.2% 54.9% z ¼ 2.06, p ¼ 0.020*
Hyperlipidemia 42.2% 48.3% z ¼ 1.86, p ¼ 0.031*
Total cholesterol 5.2  1.2 mmol/L 5.0  1.2 mmol/L t ¼ 4.68, p < 0.001*
Diabetes 9.0% 11.9% z ¼ 1.49, p ¼ 0.068
Smoking 6.1% 6.0% z ¼ 0.13, p ¼ 0.449
BMI 27.8  4.3 28.3  14.9 t ¼ 0.85, p ¼ 0.395
Key: BMI, body mass index; DCCT, Diabetes Control and Complications Trial; HbA1c,
glycated hemoglobin; HDL, high-density lipoprotein; VRF, vascular risk factors.
*p < 0.05.
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Table 5
Generalized estimating equations for VRF associations with change in WMH volume
from 73 y to 76 y
Parameter Beta Standard
error
Z p value
ICV 0.0191 mL 0.0065 mL 2.95 0.0032*
Age at baseline MRI 0.0002 %ICV 0.0002 %ICV 1.28 0.2014
0.0027 mL 0.0021 mL 1.28 0.2
Time point
(baseline vs. follow-up)
0.0915 %ICV 0.0047 %ICV 19.41 <0.0001*
1.3208 mL 0.0696 mL 18.98 <0.0001*
Systolic blood pressure at 73 y 0.0016 %ICV 0.0029 %ICV 0.57 0.5695
0.0271 mL 0.0391 mL 0.69 0.4878
Diastolic blood pressure at 73 y 0.0076 %ICV 0.0062 %ICV 1.23 0.2196
0.08 mL 0.0824 mL 0.97 0.3319
Hypertension diagnosis at 73 y 0.0634 %ICV 0.0979 %ICV 0.65 0.5169
1.128 mL 1.31 mL 0.86 0.3892
HDL ratio at 73 y 0.1451 %ICV 0.0531 %ICV 2.73 0.0063*
1.798 mL 0.7754 mL 2.32 0.0204*
Total cholesterol at 73 y 0.002 %ICV 0.0573 %ICV 0.03 0.9725
0.1366 mL 0.8266 mL 0.17 0.8687
Hyperlipidemia
diagnosis at 73 y
0.178 %ICV 0.0966 %ICV 1.84 0.0654
2.1952 mL 1.2761 mL 1.72 0.0854
HbA1c at 73 y 0.1978 %ICV 0.1154 %ICV 1.71 0.0866
2.6515 mL 1.5789 mL 1.68 0.0931
Current smoker at 73 y 0.4258 %ICV 0.1924 %ICV 2.21 0.0269*
5.4915 mL 2.5724 mL 2.13 0.0328*
Ex-smoker at 73 y 0.0383 %ICV 0.0934 %ICV 0.41 0.6817
0.6345 mL 1.2614 mL 0.5 0.6149
Diabetes diagnosis at 73 y 0.215 %ICV 0.2459 %ICV 0.87 0.3818
3.1418 mL 3.3369 mL 0.94 0.3464
Gender 0.1217 %ICV 0.0925 %ICV 1.31 0.1886
3.4228 mL 1.6715 mL 2.05 0.0406*
CVD diagnosis at 73 y 0.0539 %ICV 0.117 %ICV 0.46 0.6448
1.3817 mL 1.6171 mL 0.85 0.3929
BMI at 73 y 0.0164 %ICV 0.0134 %ICV 1.23 0.2204
0.2322 mL 0.1809 mL 1.28 0.1994
There are separate models for WMH volume divided by ICV (indicated by “%ICV”)
and WMH volume in mL with ICV added as a covariate (indicated by “mL”).
Key: BMI, body mass index; CVD, cardiovascular disease; HbA1c73, glycated he-
moglobin; HDL, high-density lipoprotein; ICV, intracranial volume; MRI, magnetic
resonance imaging; VRF, vascular risk factors; WMH, white matter hyperintensities.
*p < 0.05.
D.A. Dickie et al. / Neurobiology of Aging 42 (2016) 116e123 121that regression-based correction, rather than proportional correc-
tion, may have advantages for reducing parameter estimate errors
(Sanﬁlipo et al., 2004). This methodologic concern has apparently
received little else attention in the literature, but our regression-
based result of increased progression of WMH in females is
consistent with the higher number of strokes in females compared
with males (American Stroke Association, 2014). However, further
work is required to determine whether regression-based ap-
proaches do adequately account for ICV and whether females are
indeed at increased risk of progression of WMH in the eighth
decade of life.
WMH volume at baseline was the major determinant of WMH
change and this is conﬁrmatory of many previous reports (Sachdev
et al., 2007; Schmidt et al., 1999, 2003, 2007; Taylor et al., 2003;
Veldink et al., 1998). The relative mean increase in WMH volume
from 73 years to 76 years of 33.6% (4.0mL or 0.28% of ICV) equates to
an 11.2% relativemean increase per year. This is approximately equal
to the average rate ofWMHvolumeprogression in 3previous studies
of community-dwelling nondemented participants that found in-
creases of 6.5% (Silbert et al., 2012), 13.35% (Taylor et al., 2003), and
13.2% (Sachdev et al., 2007) per year, at ages 55e102 years (Sachdev
et al., 2007; Silbert et al., 2012; Taylor et al., 2003). The range of ages
in these other studies may explain why the mean rate of WMH
progression that we found was approximately equal to their com-
bined average rate of progression (11.2% relative mean increase per
year vs. 6.5%e13.35% per year). Furthermore, our ﬁnding that pro-
gression of WMH was least in the occipital poles is also consistent
with a previous regional analysis (Sachdev et al., 2007).
D.A. Dickie et al. / Neurobiology of Aging 42 (2016) 116e123122Our study had a number of strengths. Whereas previous studies
may have had younger and/or wide age groups where individual or
few VRF were assessed, we concurrently assessed associations be-
tween a comprehensive range of VRF and progression of WMH
exclusively in the eighth decade of life. This is an important decade
of life where the risk for dementia increases substantially
(Matthews et al., 2005). Our age-homogeneous sample of 439
community-dwelling older participants (assessed at 73 years and
76 years) provided increased statistical power to avoid a type II
error (false negative) and correctly detect associations by having
less need to statistically control for age (Freedman et al., 2007). Age
is an extremely important confounding variable in WMH as we
have previously found cross-sectional differences because of age
even within the narrow range studied in LBC1936 (Aribisala et al.,
2014). As well as the narrow age range, other novel features of
the LBC1936 study (e.g., all participants are white Caucasian) may
have minimized any potentially strong confounding effects that
factors such as mixed ethnicity and geography might have had in a
less homogeneous sample. An additional and important strength of
our study is that we measured WMH volumes using a validated,
multispectral, and quantitative technique that carefully excluded
the effect of potentially confounding infarcts (Valdés Hernández
et al., 2010; Wang et al., 2012; Wardlaw et al., 2011, 2013). Finally,
the raw brain MRI images fromwhich wemeasuredWMH volumes
were obtained using the same quality controlled protocol on the
same MRI scanner at both time points (Wardlaw et al., 2011).
Despite these strengths and consistency with previous work
(e.g., Ryu, et al., 2014; Sachdev et al., 2007; Schmidt et al., 2003;
Taylor et al., 2003; van Dijk et al., 2008), our study had limita-
tions. All but n ¼ 25 subjects appeared to have an increase in WMH
volume over time. We used a validated segmentation procedure
and individually checked WMH masks for each subject at baseline
and follow-up to minimize the effect of measurement error but
some degree of error, e.g., due to motion and/or registration, will
always be present in quantitative measurements of WMH. How-
ever, our data on WMH progression are consistent with previous
studies of community-dwelling subjects that reported limited or no
regression of WMH within measurement error (Sachdev et al.,
2007; Schmidt et al., 1999, 2003; Veldink et al., 1998). We did not
include duration of illness or self-reported use of VRF modifying
treatments, e.g., statins or antihypertensive drugs, in the GEE but
our inclusion of measured blood cholesterol, HbA1c, and blood
pressure in the analysis will have accounted for the effectiveness of
treatment to manage hypertension, diabetes, or hyperlipidemia.
There were signiﬁcant increases in the incidence of self-reported
hypertension, hyperlipidemia, history of cardiovascular disease,
and HbA1c increased on average from 73 years to 76 years. This
suggests that any VRF associations with WMH could be accounted
for by a general worsening of health. However, many of the
measured VRF were stable over time and overall participants were
still active and healthy enough to function in the community at
76 years. Participants who returned at 76 years had slightly bigger
brain volumes at 73 years compared with participants who did not
return, and therefore, the remaining participants that were used in
this analysis may be slightly biased toward healthier community-
dwelling participants. However, returning participants did not
have smaller WMH volumes, our primary outcome measure, at
73 years. Mean follow-up time was 3.7 years, and this may not be
long enough to capture large-enough changes to detect the small
inﬂuences of risk factors (Johnson et al., 2012). However, follow-up
times of approximately 3 years are common in studies and trials of
WMH progression (Brickman et al., 2012; Schmidt et al., 1999, 2012;
van Dijk et al., 2008), and we are assessing the same participants 6
years after baseline. These motivated participants score well on
cognitive tests and broader generalizations from this sample maybe limited in other populations. The narrow age range of LBC1936
precludes generalization of these results to other age groups, but
our results are not intended to be generalized to other age ranges
where VRF likely have a different impact on WMH progression
(Debette et al., 2011). We were not able to measure blood pressure
continuously but used the average of 3 sitting and 3 standing sys-
tolic and diastolic blood pressure readings obtained during a single
Clinical Research Facility assessment. Continuous monitoring
would allow assessment of other factors such as blood pressure
variability on progression of WMH volume.
Notwithstanding these limitations, we have shown that, while
blood pressure may be the most important determinant of WMH
progression in midlife (Debette et al., 2011), lower HDL cholesterol
and current smoking were the most important VRF determinants
for increased rates ofWMH progression from 73 years to 76 years of
age. This lends support to smoking cessation and further trials of
cholesterol lowering medications to reduce WMH progression in
the eighth decade of life.
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